Effectiveness and safety of an induction therapy with epoetin alfa in anemic cancer patients receiving concomitant chemotherapy

Enrico Cortesi; Andrea Mancuso; Adolfo De Pasquale Ceratti; Nicolina Pizzardi; Giuliana D'Auria; Caterina Accettura; Patrizia Beccaglia; Daniela Bertelletti; Filippo De Marinis

doi:10.1634/theoncologist.9-4-459

Effectiveness and safety of an induction therapy with epoetin alfa in anemic cancer patients receiving concomitant chemotherapy

Enrico Cortesi, Andrea Mancuso, Adolfo De Pasquale Ceratti, Nicolina Pizzardi, Giuliana D'Auria, Caterina Accettura, Patrizia Beccaglia, Daniela Bertelletti, Filippo De Marinis

Istituto Europeo di Oncologia

Research output: Contribution to journal › Article › peer-review

Abstract

Background. Epoetin alfa, administered at standard dosages of 10,000-20,000 IU three times weekly or 40,000-60,000 IU once weekly, has been shown to significantly increase hemoglobin (Hb) levels, decrease transfusion requirements, and improve quality-of-life parameters in patients undergoing chemotherapy. Objective. This open-label, nonrandomized, historically controlled study was conducted to evaluate the efficacy and safety of an induction dose of epoetin alfa in patients with moderate or severe anemia who were receiving chemotherapy. Methods. Nineteen patients with solid tumors and Hb levels

Original language	English
Pages (from-to)	459-468
Number of pages	10
Journal	The oncologist
Volume	9
Issue number	4
DOIs	https://doi.org/10.1634/theoncologist.9-4-459
Publication status	Published - 2004

Keywords

Anemia
Cancer
Epoetin alfa
Hemoglobin
Induction therapy

ASJC Scopus subject areas

Cancer Research
Hematology

Access to Document

10.1634/theoncologist.9-4-459

Fingerprint Dive into the research topics of 'Effectiveness and safety of an induction therapy with epoetin alfa in anemic cancer patients receiving concomitant chemotherapy'. Together they form a unique fingerprint.

Cite this

Effectiveness and safety of an induction therapy with epoetin alfa in anemic cancer patients receiving concomitant chemotherapy. / Cortesi, Enrico; Mancuso, Andrea; De Pasquale Ceratti, Adolfo; Pizzardi, Nicolina; D'Auria, Giuliana; Accettura, Caterina; Beccaglia, Patrizia; Bertelletti, Daniela; De Marinis, Filippo.

In: The oncologist, Vol. 9, No. 4, 2004, p. 459-468.

Research output: Contribution to journal › Article › peer-review

Cortesi, Enrico ; Mancuso, Andrea ; De Pasquale Ceratti, Adolfo ; Pizzardi, Nicolina ; D'Auria, Giuliana ; Accettura, Caterina ; Beccaglia, Patrizia ; Bertelletti, Daniela ; De Marinis, Filippo. / Effectiveness and safety of an induction therapy with epoetin alfa in anemic cancer patients receiving concomitant chemotherapy. In: The oncologist. 2004 ; Vol. 9, No. 4. pp. 459-468.

@article{2e91722df6584d66b6aee65ac2b9bcd3,

title = "Effectiveness and safety of an induction therapy with epoetin alfa in anemic cancer patients receiving concomitant chemotherapy",

abstract = "Background. Epoetin alfa, administered at standard dosages of 10,000-20,000 IU three times weekly or 40,000-60,000 IU once weekly, has been shown to significantly increase hemoglobin (Hb) levels, decrease transfusion requirements, and improve quality-of-life parameters in patients undergoing chemotherapy. Objective. This open-label, nonrandomized, historically controlled study was conducted to evaluate the efficacy and safety of an induction dose of epoetin alfa in patients with moderate or severe anemia who were receiving chemotherapy. Methods. Nineteen patients with solid tumors and Hb levels ",

keywords = "Anemia, Cancer, Epoetin alfa, Hemoglobin, Induction therapy",

author = "Enrico Cortesi and Andrea Mancuso and {De Pasquale Ceratti}, Adolfo and Nicolina Pizzardi and Giuliana D'Auria and Caterina Accettura and Patrizia Beccaglia and Daniela Bertelletti and {De Marinis}, Filippo",

year = "2004",

doi = "10.1634/theoncologist.9-4-459",

language = "English",

volume = "9",

pages = "459--468",

journal = "Oncologist",

issn = "1083-7159",

publisher = "Wiley Blackwell",

number = "4",

}

TY - JOUR

T1 - Effectiveness and safety of an induction therapy with epoetin alfa in anemic cancer patients receiving concomitant chemotherapy

AU - Cortesi, Enrico

AU - Mancuso, Andrea

AU - De Pasquale Ceratti, Adolfo

AU - Pizzardi, Nicolina

AU - D'Auria, Giuliana

AU - Accettura, Caterina

AU - Beccaglia, Patrizia

AU - Bertelletti, Daniela

AU - De Marinis, Filippo

PY - 2004

Y1 - 2004

N2 - Background. Epoetin alfa, administered at standard dosages of 10,000-20,000 IU three times weekly or 40,000-60,000 IU once weekly, has been shown to significantly increase hemoglobin (Hb) levels, decrease transfusion requirements, and improve quality-of-life parameters in patients undergoing chemotherapy. Objective. This open-label, nonrandomized, historically controlled study was conducted to evaluate the efficacy and safety of an induction dose of epoetin alfa in patients with moderate or severe anemia who were receiving chemotherapy. Methods. Nineteen patients with solid tumors and Hb levels

AB - Background. Epoetin alfa, administered at standard dosages of 10,000-20,000 IU three times weekly or 40,000-60,000 IU once weekly, has been shown to significantly increase hemoglobin (Hb) levels, decrease transfusion requirements, and improve quality-of-life parameters in patients undergoing chemotherapy. Objective. This open-label, nonrandomized, historically controlled study was conducted to evaluate the efficacy and safety of an induction dose of epoetin alfa in patients with moderate or severe anemia who were receiving chemotherapy. Methods. Nineteen patients with solid tumors and Hb levels

KW - Anemia

KW - Cancer

KW - Epoetin alfa

KW - Hemoglobin

KW - Induction therapy

UR - http://www.scopus.com/inward/record.url?scp=3543024463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3543024463&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.9-4-459

DO - 10.1634/theoncologist.9-4-459

M3 - Article

C2 - 15266099

AN - SCOPUS:3543024463

VL - 9

SP - 459

EP - 468

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 4

ER -